Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Future Oncol
; 11(4): 629-40, 2015.
Article
in En
| MEDLINE
| ID: mdl-25686118
ABSTRACT
AIM:
To explore the prognostic value of extended mutational profiling for metastatic colorectal cancer (mCRC). MATERIALS &METHODS:
We retrospectively reviewed survival results of 194 mCRC patients that were assigned to four molecular subgroups BRAF mutated; KRAS mutated codons 12-13 only; any of KRAS codons 61-146, PIK3CA or NRAS mutations and all wild-type. Point mutations were investigated by pyrosequencing.RESULTS:
BRAF (5.2%) and KRAS 12-13 (31.9%) mutations were associated with poorer survival (HR 2.8 and 1.76, respectively). Presenting with right-sided colon cancer, not resected primary tumor, WBC >10 × 10(9)/l, receiving less chemotherapy or no bevacizumab were all associated with inferior outcome. The all-wild-type subgroup (39.2%) reported the longest survival.CONCLUSION:
Extended mutational profile combined with clinical factors may impact on survival in mCRC.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Proto-Oncogene Proteins
/
Ras Proteins
/
Phosphatidylinositol 3-Kinases
/
Proto-Oncogene Proteins B-raf
/
GTP Phosphohydrolases
/
Membrane Proteins
/
Mutation
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Future Oncol
Year:
2015
Type:
Article
Affiliation country:
Italy